Chelsea Therapeutics International LTD (CHTP) financial statements (2023 and earlier)
Company profile
| Business Address |
3530 TORINGDON WAY CHARLOTTE, NC 28277 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 45,323 | 28,425 | ||
| Cash and cash equivalents | 45,323 | 28,425 | ||
| Prepaid expense | 915 | ✕ | ||
| Prepaid expense and other current assets | ✕ | 176 | ||
| Other undisclosed current assets | 220 | 175 | ||
| Total current assets: | 46,458 | 28,776 | ||
| Noncurrent Assets | ||||
| Property, plant and equipment | 45 | 152 | ||
| Total noncurrent assets: | 45 | 152 | ||
| TOTAL ASSETS: | 46,503 | 28,928 | ||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 1,949 | 1,485 | ||
| Accounts payable | 1,363 | 788 | ||
| Accrued liabilities | 372 | 497 | ||
| Employee-related liabilities | 213 | 200 | ||
| Total current liabilities: | 1,949 | 1,485 | ||
| Noncurrent Liabilities | ||||
| Other undisclosed liabilities | 1,298 | 1,526 | ||
| Total liabilities: | 3,247 | 3,011 | ||
| Stockholders' equity | ||||
| Stockholders' equity attributable to parent, including: | 43,256 | 25,916 | ||
| Common stock | 8 | 7 | ||
| Additional paid in capital | 274,725 | 240,971 | ||
| Other undisclosed stockholders' equity attributable to parent | (231,478) | (215,061) | ||
| Total stockholders' equity: | 43,256 | 25,916 | ||
| TOTAL LIABILITIES AND EQUITY: | 46,503 | 28,928 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|
| Operating expenses | (16,434) | (31,804) | |
| Operating loss: | (16,434) | (31,804) | |
| Nonoperating income (Investment Income, Nonoperating) | 18 | 68 | |
| Net loss available to common stockholders, diluted: | (16,416) | (31,736) | |
Comprehensive Income ($ in thousands)
| 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|
| Net loss: | (16,416) | (31,736) | |
| Comprehensive loss, net of tax, attributable to parent: | (16,416) | (31,736) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.